Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01300247
Other study ID # GAO4779g
Secondary ID GO01298
Status Completed
Phase Phase 1
First received February 14, 2011
Last updated March 4, 2016
Start date June 2011
Est. completion date December 2015

Study information

Verified date March 2016
Source Genentech, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This open-label, 2-arm, nonrandomized, multicenter, Phase Ib study will investigate the safety and efficacy of RO5072759 (GA101) administered in combination with chemotherapy (bendamustine or FC regimens) in patients with previously untreated CD20-positive B-CLL. Patients will be enrolled to receive a maximum of 6 cycles of GA101 (1000mg iv infusion, on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2 - 6) plus bendamustine (90 mg/m2 IV, on days 2 and 3 of cycle 1 and days 1 and 2 of cycles 2 - 6) on 28 day cycles or a maximum of 6 cycles of GA101 (1000mg iv infusion, on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2 - 6) plus FC (fludarabine 25 mg/m2 IV on days 2, 3 and 4 of cycle 1 and days 1, 2 and 3 of cycles 2 - 6; cyclophosphamide 250 mg/m2 IV on days 2, 3 and 4 of cycle 1 and days 1, 2 and 3 of cycles 2 - 6) on 28 day cycles.


Recruitment information / eligibility

Status Completed
Enrollment 41
Est. completion date December 2015
Est. primary completion date January 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Confirmed diagnosis of CD20-positive B-CLL

- Rai Stage III/IV or Binet Stage C disease

- Rai Stage I/II or Binet Stage B disease that requires treatment

- Adequate baseline bone marrow function, unless there is clear evidence of extensive bone marrow involvement with tumor infiltration, myelodysplasia, or hypocellularity

- No previous treatment for CLL by chemotherapy, radiotherapy, or immunotherapy

- ECOG performance status of 0, 1, or 2

- Life expectancy of > 6 months

Exclusion Criteria:

- Treatment with any other investigational agent or participation in another clinical trial within 28 days prior to the start of Cycle 1

- Transformation of CLL to aggressive B-cell malignancy

- Creatinine clearance =< 60 mL/min, calculated according to the formula of Cockroft and Gault

- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 times the upper limit of normal (ULN)

- Total bilirubin >= 3 x ULN

- History of severe allergic or anaphylactic reactions to monoclonal antibody therapy

- History of sensitivity to mannitol (if bendamustine is to be administered)

- History of other malignancy that could affect compliance with the protocol or interpretation of results

- Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease or pulmonary disease

- Known active bacterial, viral, fungal, mycobacterial, or other infection (excluding fungal infections of nail beds) or any major episode of infection requiring treatment with IV antibiotics or hospitalization (related to the completion of the course of antibiotics) within 4 weeks before the start of Cycle 1

- Recent major surgery (within 4 weeks prior to the start of Cycle 1), other than for diagnosis

- Known infection with human immunodeficiency virus (HIV) seropositive status

- Presence of positive test results for hepatitis B (hepatitis B virus [HBV] surface antigen [HBsAg] and/or total hepatitis B core antibody [anti-HBc]) or hepatitis C (hepatitis C virus [HCV] antibody serology testing). Patients with chronic HBV infection, occult HBV infection, or past HBV infection will be excluded. Patients who have received IVIG within 3 months of enrollment and who are anti-HBc positive but HBV DNA negative will be considered for inclusion on the study by the Medical Monitor on a case-by-case basis. Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA.

- Women who are pregnant or lactating

- Fertile men or women of childbearing potential unless 1) surgically sterile or 2) using an adequate measure of contraception such as oral contraceptives, intrauterine device, or barrier method of contraception in conjunction with spermicidal jelly

- Concurrent (or within 7 days prior to the first dose of study treatment) systemic corticosteroid use except low-dose corticosteroid therapy used to treat an illness other than lymphoma

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Fludarabine
Intravenous repeating dose
RO5072759
Intravenous repeating dose
bendamustine
Intravenous repeating dose
cyclophosphamide
Intravenous repeating dose

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical laboratory abnormalities Up to 3 years No
Primary Incidence of adverse events Up to 3 years No
Primary Incidence of human anti-human antibodies (HAHAs) Up to 6 months after end of treatment No
Primary Nature of adverse events Up to 3 years No
Primary Severity of adverse events Up to 3 years No
Secondary Pharmacokinetic parameters derived from plasma concentration-time profiles of GA101 following administration Up to Day 141 No
Secondary Objective response rate Up to 3 months after end of treatment No
Secondary Duration of response Up to 3 years after end of treatment No
Secondary Progression free survival Up to 3 years after end of treatment No
Secondary Overall survival, defined as the time from randomization until death from any cause up to 3.5 years No
Secondary Pharmacodynamics: Peripheral blood B-cell depletion and recovery Up to Day 141 No
See also
  Status Clinical Trial Phase
Completed NCT01072240 - An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia N/A
Completed NCT00754650 - A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia Phase 2
Active, not recruiting NCT02500407 - A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Phase 1/Phase 2
Recruiting NCT04704323 - CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Active, not recruiting NCT01414205 - A Study Comparing RO5072759 (GA101) 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GAGE) Phase 2
Completed NCT01224093 - An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC) N/A
Completed NCT01395615 - An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic Leukaemia N/A
Completed NCT00532129 - A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia. Phase 2
Completed NCT02013817 - CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy Phase 2
Completed NCT01685892 - A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia Phase 1
Completed NCT00738374 - A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia. Phase 2
Completed NCT00241358 - Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies Phase 1/Phase 2
Completed NCT01056510 - A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) Phase 4
Terminated NCT01271010 - A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status Phase 4
Completed NCT00718549 - A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL) Phase 3
Completed NCT01263704 - A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia Phase 2
Completed NCT00431873 - A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia Phase 2
Completed NCT01178086 - A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
Terminated NCT02292225 - Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY) Phase 1
Completed NCT02533401 - A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL) Phase 2